These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 7755777)
21. [Controversies in the treatment of acute myeloid leukemia of the adult. Chemotherapy vs bone marrow transplantation]. Tartas N; Grassi D Medicina (B Aires); 1991; 51(4):361-4. PubMed ID: 1821928 [No Abstract] [Full Text] [Related]
22. [The current chemotherapy of acute myeloid leukemias in adults]. Poddubnaia IV; Perilov AA Ter Arkh; 1993; 65(7):86-9. PubMed ID: 8211791 [No Abstract] [Full Text] [Related]
23. [Therapy of patients with myeloid leukemia with small doses of cytosine arabinoside]. Patterson D; Kravtsova VM; Petrova EM; Zabelina TS; Balaian LN Ter Arkh; 1987; 59(12):81-6. PubMed ID: 3482131 [TBL] [Abstract][Full Text] [Related]
24. Shedding of the nails due to chemotherapy (onychomadesis). Cetin M; Utas S; Unal A; Altinbas M J Eur Acad Dermatol Venereol; 1998 Sep; 11(2):193-4. PubMed ID: 9784057 [No Abstract] [Full Text] [Related]
25. Nail toxicities induced by systemic anticancer treatments. Robert C; Sibaud V; Mateus C; Verschoore M; Charles C; Lanoy E; Baran R Lancet Oncol; 2015 Apr; 16(4):e181-9. PubMed ID: 25846098 [TBL] [Abstract][Full Text] [Related]
26. Intensive chemotherapy with daunorubicin, 5-azacytidine, 6-thioguanine, and cytarabine (DATA) for the blastic transformation of chronic granulocytic leukemia. Winton EF; Miller D; Vogler WR Cancer Treat Rep; 1981; 65(5-6):389-92. PubMed ID: 6165470 [TBL] [Abstract][Full Text] [Related]
27. Case report showed Muehrcke's nails, not Beau's lines. Möhrenschlager M; Abeck D; Ring J BMJ; 2003 Jan; 326(7380):105. PubMed ID: 12521984 [No Abstract] [Full Text] [Related]
29. What do Beau's lines mean? De Berker D Int J Dermatol; 1994 Aug; 33(8):545-6. PubMed ID: 7960346 [No Abstract] [Full Text] [Related]
30. Mitoxantrone versus daunorubicin in induction-consolidation chemotherapy--the value of low-dose cytarabine for maintenance of remission, and an assessment of prognostic factors in acute myeloid leukemia in the elderly: final report. European Organization for the Research and Treatment of Cancer and the Dutch-Belgian Hemato-Oncology Cooperative Hovon Group. Löwenberg B; Suciu S; Archimbaud E; Haak H; Stryckmans P; de Cataldo R; Dekker AW; Berneman ZN; Thyss A; van der Lelie J; Sonneveld P; Visani G; Fillet G; Hayat M; Hagemeijer A; Solbu G; Zittoun R J Clin Oncol; 1998 Mar; 16(3):872-81. PubMed ID: 9508168 [TBL] [Abstract][Full Text] [Related]
31. Beau's Lines and Leukonychia in a COVID-19 Patient. Ide S; Morioka S; Inada M; Ohmagari N Intern Med; 2020 Dec; 59(24):3259. PubMed ID: 33132338 [No Abstract] [Full Text] [Related]
32. [The therapeutic results in acute myeloid leukemias in elderly patients]. Parovichnikova EN; Savchenko VG; Isaev VG; Tikhonova LIu; Sarycheva TG; Kulikov SM Ter Arkh; 1992; 64(8):87-9. PubMed ID: 1440406 [No Abstract] [Full Text] [Related]
33. [The results of a multicenter cooperative study on treating acute myeloid leukemias in adults]. Savchenko VG; Parovichnikova EN; Kliasova GA; Isaev VG; Kulikov SM; Tikhonova LIu; Cherepanova VV; Rekhtman GB; Medvedeva NV; Kaporskaia TS Ter Arkh; 1994; 66(7):11-7. PubMed ID: 7985120 [No Abstract] [Full Text] [Related]
34. Development of Beau's lines in two patients receiving azathioprine. Makhzoumi Z; DeCapite T; Gaspari A J Dermatolog Treat; 2009; 20(4):246-7. PubMed ID: 19255920 [TBL] [Abstract][Full Text] [Related]
35. Increasing dose intensity of anthracycline antibiotics improves outcome in patients with acute myelogenous leukemia. Novitzky N; Thomas V; Abrahams L; du Toit C; McDonald A Am J Hematol; 2004 Aug; 76(4):319-29. PubMed ID: 15282663 [TBL] [Abstract][Full Text] [Related]
36. Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B Study 9621. Kolitz JE; George SL; Dodge RK; Hurd DD; Powell BL; Allen SL; Velez-Garcia E; Moore JO; Shea TC; Hoke E; Caligiuri MA; Vardiman JW; Bloomfield CD; Larson RA; J Clin Oncol; 2004 Nov; 22(21):4290-301. PubMed ID: 15514371 [TBL] [Abstract][Full Text] [Related]
37. [Daunomycin-induced cardiogenic shock in a case of acute myelogenous leukemia]. Matsuda S; Shineha H; Kokubun K; Yoshida M; Sakai K; Yui T; Kimura H; Uchida T; Kariyone S Rinsho Ketsueki; 1987 Sep; 28(9):1680-5. PubMed ID: 3481411 [No Abstract] [Full Text] [Related]
38. The impact of early intensive therapy on event-free survival (EFS) in children with acute myeloid leukemia (AML). Weinstein H; Ravindranath Y; Krischer J; Steuber P; Civin C; Gresik M; Vietti T Leukemia; 1992; 6 Suppl 2():52-4. PubMed ID: 1578941 [No Abstract] [Full Text] [Related]
39. Comparison of fludarabine-containing salvage chemotherapy regimens for relapsed/refractory acute myelogenous leukemia. Thomas MB; Koller C; Yang Y; Shen Y; O'Brien S; Kantarjian H; Davis J; Estey E Leukemia; 2003 May; 17(5):990-3. PubMed ID: 12750721 [No Abstract] [Full Text] [Related]
40. Intensive individualized induction therapy with behenoyl cytarabine, daunorubicin and 6-mercaptopurine followed by intensive consolidation including intermediate-dose continuous cytarabine, mitoxantron, etoposide and vinca alkaloids in acute myeloid leukemia in adults. Ohno R; Yokomaku S; Okumura M; Nagai T; Kitaori K; Ito T; Takeo T; Sugiura I; Yano K; Ito Y Int J Hematol; 1991 Dec; 54(6):487-93. PubMed ID: 1793832 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]